Eight Roads Ventures, F-Prime Capital completed the acquisition of a 8% stake in Enzene Biosciences for $20m.

Synopsis

Private equity firms Eight Roads Ventures, F-Prime Capital completed the acquisition of a 8% stake in Enzene Biosciences, a biotechnology company, for $20m.

Principals

target

Enzene Biosciences

bidder

F-prime Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

ernst & young

HQ - London

financial advisors

target

3952

Deals

£ 978.59 B

Total Value

cyril amarchand mangaldas

HQ - Mumbai

legal advisors

target

252

Deals

£ 157.43 B

Total Value